Nanopharmacology of Liposomes Developed for Cancer Therapy

Abstract

the necessary bending energy [5]. Liposomes are a promising dosage form/drug delivery system owing to their size, hydrophobic and hydrophilic character, biocompatibility, biodegradability, low toxicity and immunogenicity [6,7]. Indeed, liposome products were the first nanopharmaceuticals approved by the US FDA and are listed in the database of dosage forms with a FDA code of 852 [101]. Stealth liposomes are an emerging novel development in the technology to enhance their half-life in the bloodstream. Generally, the surfaces of these liposomes are modified with the attachment of polyethylene glycol (PEG) groups to the liposomal bilayer to avoid the opsonization process [8].